See more : IPE Group Limited (0929.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Purple Biotech Ltd. (PPBT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Purple Biotech Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Moon Environment Technology Co.,Ltd. (000811.SZ) Income Statement Analysis – Financial Results
- InnoCare Optoelectronics Corporation (6861.TW) Income Statement Analysis – Financial Results
- Sunnyside Bancorp, Inc. (SNNY) Income Statement Analysis – Financial Results
- Tamilnad Mercantile Bank Limited (TMB.NS) Income Statement Analysis – Financial Results
- Aries Agro Limited (ARIES.NS) Income Statement Analysis – Financial Results
Purple Biotech Ltd. (PPBT)
About Purple Biotech Ltd.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | -910.00K | -320.00K | 1.00M | 1.00M | 1.00M | 901.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 196.00K | 201.00K | 231.00K | 235.00K | 80.00 | 0.00 | 4.00K | 2.00K | 999.76 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -196.00K | -1.11M | -551.00K | 765.00K | 999.92K | 1.00M | 897.00K | -2.00K | -999.76 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 122.09% | 172.19% | 76.50% | 99.99% | 100.00% | 99.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 17.03M | 16.32M | 11.83M | 7.49M | 2.67M | 5.27M | 4.64M | 4.18M | 2.56M | 3.19M | 109.00K | 94.00 |
| General & Administrative | 0.00 | 5.96M | 5.82M | 6.07M | 6.08M | 4.45M | 6.39M | 3.00M | 1.51M | 1.27M | 1.06M | 608.00 |
| Selling & Marketing | 0.00 | 321.00K | 286.00K | 235.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.04M | 6.28M | 6.11M | 6.31M | 6.08M | 4.45M | 6.39M | 3.00M | 1.51M | 1.27M | 1.06M | 608.00 |
| Other Expenses | -44.54M | 0.00 | 0.00 | -15.66M | -216.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -22.47M | 22.60M | 17.93M | 13.79M | 8.75M | 8.83M | 12.06M | 7.18M | 4.07M | 5.18M | 1.17M | 703.00 |
| Cost & Expenses | -22.27M | 22.60M | 17.93M | 13.79M | 8.75M | 8.83M | 12.06M | 7.18M | 4.07M | 5.18M | 1.17M | 703.00 |
| Interest Income | 474.00K | 969.00K | 320.00K | 254.00K | 151.00K | 93.00K | 106.00K | 138.00K | 94.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.18M | 126.00K | 212.00K | 61.00K | 181.00K | 576.00K | 26.00K | 6.00K | 3.00K | 21.00K | 48.00K | 0.00 |
| Depreciation & Amortization | 199.00K | 201.00K | 231.00K | 235.00K | 178.00K | 7.00K | 4.00K | 2.00K | 1.00K | -50.00K | -27.00K | 957.22 |
| EBITDA | -22.23M | -21.49M | -17.52M | -28.41M | -6.14M | -5.55M | -12.88M | -7.04M | -4.20M | -5.43M | -2.58M | 255.22 |
| EBITDA Ratio | 0.00% | 2,355.27% | 5,432.19% | -2,796.00% | -763.80% | -772.60% | -1,323.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 22.27M | -22.60M | -17.93M | 12.61M | -7.16M | -7.83M | -12.25M | -7.18M | -4.07M | -5.18M | -2.55M | -702.00 |
| Operating Income Ratio | 0.00% | 2,483.85% | 5,604.38% | 1,261.20% | -715.60% | -782.60% | -1,359.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -42.25M | -43.52M | 108.00K | -15.46M | 1.48M | 2.26M | -947.00K | -4.94M | -133.00K | -71.00K | -75.00K | -1.00 |
| Income Before Tax | -19.98M | -21.76M | -17.83M | -28.07M | -5.89M | -5.57M | -13.01M | -12.13M | -4.20M | -5.25M | -2.63M | -703.00 |
| Income Before Tax Ratio | 0.00% | 2,391.21% | 5,570.63% | -2,807.40% | -589.30% | -556.90% | -1,443.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -935.00K | 637.00K | -15.67M | 216.00K | -2.63M | 26.00K | 4.94M | 133.00K | 50.00K | 27.00K | 0.00 |
| Net Income | -19.88M | -20.83M | -18.46M | -12.41M | -6.11M | -5.20M | -12.27M | -12.13M | -4.20M | -5.25M | -2.63M | -703.00 |
| Net Income Ratio | 0.00% | 2,288.46% | 5,769.69% | -1,240.50% | -610.90% | -520.00% | -1,362.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.09 | -1.13 | -1.04 | -0.72 | -3.15 | -0.27 | -0.63 | -0.62 | -0.22 | -234.38 | -320.25 | -10.49 |
| EPS Diluted | -0.09 | -1.13 | -1.04 | -0.72 | -3.15 | -0.27 | -0.63 | -0.62 | -0.22 | -234.38 | -320.25 | -10.41 |
| Weighted Avg Shares Out | 221.33M | 18.48M | 17.80M | 17.21M | 1.94M | 19.54M | 19.54M | 19.54M | 19.54M | 22.41K | 8.21K | 67.00 |
| Weighted Avg Shares Out (Dil) | 221.33M | 18.48M | 17.80M | 17.21M | 1.94M | 19.54M | 19.54M | 19.54M | 19.54M | 22.41K | 8.21K | 67.55 |
Purple Biotech Announces Closing of $5 Million Registered Direct Offering
REHOVOT, Israel, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance,...
Purple Biotech Announces $5 Million Registered Direct Offering
REHOVOT, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance,...
Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action
REHOVOT, Israel, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance,...
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
REHOVOT, Israel, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, ...
Purple Biotech Reports Second Quarter 2023 Financial Results
Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 study Clinical data from both studies expected in the coming months Cash runway extended into H1 2025
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
REHOVOT, Israel, July 11, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance,...
Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference
REHOVOT, Israel, April 18, 2023 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment (TME) to overcome...
Purple Biotech to Present at the Jefferies London Healthcare Conference
REHOVOT, Israel, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that management...
Purple Biotech to Present at the Jefferies Virtual Healthcare Conference
REHOVOT, Israel, May 26, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced that management will...
Purple Biotech to Present New Clinical Data from NT219 at the 2021 ASCO Annual Meeting
Initial Data from Ongoing Phase 1/2 Clinical Trial of NT219 in Adults with Advanced Solid Tumors and Head and Neck Cancer to be Highlighted
Source: https://incomestatements.info
Category: Stock Reports